AstraZeneca PLC (NASDAQ:AZN) Holdings Lowered by Vestcor Inc

Vestcor Inc trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 43.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,100 shares of the company’s stock after selling 10,100 shares during the period. Vestcor Inc’s holdings in AstraZeneca were worth $1,021,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AZN. Martin Investment Management LLC grew its stake in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after buying an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC grew its holdings in AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning increased its position in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the period. Northcape Wealth Management LLC bought a new position in shares of AstraZeneca during the 2nd quarter worth about $269,000. Finally, Soros Fund Management LLC increased its position in shares of AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after purchasing an additional 201,233 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Trading Down 0.7 %

AZN stock opened at $66.94 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a market cap of $207.55 billion, a P/E ratio of 32.03, a PEG ratio of 1.20 and a beta of 0.45. The business has a fifty day moving average of $70.39 and a 200-day moving average of $76.80.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 EPS. As a group, equities research analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.